AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17192165 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (standard therapy)
Number of subjects: 0
Study 16380617 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.5 to 1.5 mg/kg/day)
Number of subjects: 148
Study 16380617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 11926625 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 670
Study 11926625 — intervention group
Group type: COMPARATOR
Intervention: Conventional asthma therapy (CAT)
Number of subjects: 670
Study 9616506 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (10(-9), 10(-7), and 10(-5) M)
Number of subjects: 9
Study 9616506 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (10(-8), 10(-6), and 10(-4) M)
Number of subjects: 9
Study 9616506 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 9
Study 8604540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid 0.075 g daily for 2 months
Number of subjects: 45
Study 8604540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid 0.15 g daily for 1 month
Number of subjects: 45
Study 8604540 — intervention group
Group type: COMPARATOR
Intervention: Control group (local hypotensive therapy only)
Number of subjects: 45
Study 2561121 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEp)
Number of subjects: 0
Study 2561121 — intervention group
Group type: COMPARATOR
Intervention: Natural erythropoietin
Number of subjects: 0
Study 334476 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg flurbiprofen daily
Number of subjects: 12
Study 334476 — intervention group
Group type: COMPARATOR
Intervention: 400 mg phenylbutazone daily
Number of subjects: 12
Study 30629123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical and regional β‐amyloid (Aβ) in the anterior putamen
Number of subjects: 269
Study 30629123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical and regional β‐amyloid (Aβ) in the posterior putamen
Number of subjects: 269
Study 30629123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical and regional β‐amyloid (Aβ) in the precuneus
Number of subjects: 269
Study 28192627 — intervention group
Group type: EXPERIMENTAL
Intervention: New pathway (NP) with perioperative home visits by enterostomal therapists
Number of subjects: 218
Study 28192627 — intervention group
Group type: COMPARATOR
Intervention: Standard pathway (SP)
Number of subjects: 218
Study 25348510 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 0.1 μg/kg/min
Number of subjects: 20
Study 25348510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23562219 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN-AA
Number of subjects: 19
Study 23562219 — intervention group
Group type: COMPARATOR
Intervention: Standard-AA
Number of subjects: 19
Study 21942782 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of item presentation (1, 5, and 10 s) with reencoding
Number of subjects: 36
Study 21942782 — intervention group
Group type: COMPARATOR
Intervention: Shorter duration of item presentation
Number of subjects: 36
Study 21942782 — intervention group
Group type: EXPERIMENTAL
Intervention: Reencoding possibility (none, immediately after the study phase, after 1 hr)
Number of subjects: 36
Study 19369318 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 421
Study 19369318 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 421
Study 19369318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 421
Study 19369318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 16776683 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant cherry allergen ImmunoCAP (rPru av 1, 3 and 4)
Number of subjects: 186
Study 16776683 — intervention group
Group type: COMPARATOR
Intervention: Cherry extract
Number of subjects: 186
Study 16776683 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant allergen ImmunoCAP
Number of subjects: 186
Study 16776683 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test (SPT)
Number of subjects: 186
Study 16776683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pru av 3 sensitization in Spanish patients
Number of subjects: 186
Study 16776683 — intervention group
Group type: EXPERIMENTAL
Intervention: LTP sensitization in German patients
Number of subjects: 186
Study 15522252 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 20
Study 15522252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11094441 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell transplantation (HSC)
Number of subjects: 350
Study 11094441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense regimens
Number of subjects: 350
Study 11094441 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 350
Study 9314625 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise program (12 weekly group sessions, 1 individual session, and 6 biweekly group sessions)
Number of subjects: 64
Study 9314625 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss and exercise program
Number of subjects: 64
Study 9314625 — intervention group
Group type: COMPARATOR
Intervention: Usual care (1 individual session, and 6 biweekly group sessions)
Number of subjects: 64
Study 9314625 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 8394192 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of elcatonin (carbocalcitonin) and conjugated estrogens with medroxyprogesterone acetate
Number of subjects: 0
Study 8394192 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin alone
Number of subjects: 0
Study 8394192 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens with medroxyprogesterone acetate alone
Number of subjects: 0
Study 8394192 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 3552679 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose digoxin
Number of subjects: 14
Study 3552679 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with verapamil (120 mg daily)
Number of subjects: 14
Study 3552679 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with verapamil
Number of subjects: 14
Study 3552679 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin and verapamil
Number of subjects: 14
Study 31732098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk)
Number of subjects: 1051
Study 31732098 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily, 4 wk on, 2 wk off)
Number of subjects: 1051
Study 31732098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 1051
Study 30458877 — intervention group
Group type: EXPERIMENTAL
Intervention: Discovery then Instruction group
Number of subjects: 34
Study 30458877 — intervention group
Group type: COMPARATOR
Intervention: Instruction then Discovery group
Number of subjects: 34
Study 30458877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 27053382 — intervention group
Group type: EXPERIMENTAL
Intervention: extruded FePP‐fortified rice (No CA/TSC)
Number of subjects: 20
Study 27053382 — intervention group
Group type: EXPERIMENTAL
Intervention: extruded FePP‐fortified rice with CA/TSC added before extrusion (CA/TSC extruded)
Number of subjects: 20
Study 27053382 — intervention group
Group type: EXPERIMENTAL
Intervention: extruded FePP‐fortified rice with CA/TSC solution added after cooking (CA/TSC solution)
Number of subjects: 20
Study 27053382 — intervention group
Group type: COMPARATOR
Intervention: nonextruded rice fortified with a FeSO4 solution added after cooking (reference)
Number of subjects: 20
Study 24765679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteric stent with extraction string
Number of subjects: 68
Study 24765679 — intervention group
Group type: COMPARATOR
Intervention: Ureteric stent without extraction string
Number of subjects: 68
Study 22583089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative norm
Number of subjects: 128
Study 22583089 — intervention group
Group type: COMPARATOR
Intervention: Competitive norm
Number of subjects: 128
Study 22583089 — intervention group
Group type: COMPARATOR
Intervention: Neutral norm
Number of subjects: 128
Study 20420724 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic tube compensation (ATC)
Number of subjects: 118
Study 20420724 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 118
Study 17505923 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 947
Study 16338253 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting TAXUS stent
Number of subjects: 1314
Study 16338253 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 1314
Study 11888954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental appliance
Number of subjects: 95
Study 11888954 — intervention group
Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 95
Study 10443077 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT and flupenthixol (12‐24 mg/d)
Number of subjects: 114
Study 10443077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined C‐ECT and flupenthixol
Number of subjects: 114
Study 10443077 — intervention group
Group type: COMPARATOR
Intervention: C‐ECT alone
Number of subjects: 114
Study 10443077 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol alone
Number of subjects: 114
Study 7589058 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with ascorbic acid (2 g)
Number of subjects: 0
Study 7589058 — intervention group
Group type: COMPARATOR
Intervention: Propranolol without ascorbic acid (control)
Number of subjects: 0
Study 2148876 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 214
Study 2148876 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 214
Study 7352858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg/day)
Number of subjects: 43
Study 7352858 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 43
Study 30520976 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of whole-body fat
Number of subjects: 3460
Study 30520976 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of trunk fat mass
Number of subjects: 3460
Study 30520976 — intervention group
Group type: EXPERIMENTAL
Intervention: Uppermost quartile of trunk fat mass
Number of subjects: 3460
Study 28177745 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate milk
Number of subjects: 52
Study 28177745 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt drink
Number of subjects: 52
Study 28177745 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Milk
Number of subjects: 52
Study 28177745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit punch
Number of subjects: 52
Study 28177745 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 52
Study 28177745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese children
Number of subjects: 52
Study 26455135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS) assisted with the lesser trochanteric reduction fixation system
Number of subjects: 66
Study 26455135 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS) only
Number of subjects: 66
Study 22823594 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg slow release taken orally twice daily for 2.5 days
Number of subjects: 19
Study 22823594 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken orally twice daily for 2.5 days
Number of subjects: 19
Study 22067548 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reading vignettes about injury-related disabilities
Number of subjects: 0
Study 22067548 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reading vignettes about illness-related disabilities
Number of subjects: 0
Study 22067548 — intervention group
Group type: EXPERIMENTAL
Intervention: Female with an illness-related disability vignette
Number of subjects: 0
Study 22067548 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible disability vignette
Number of subjects: 0
Study 19601995 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 0
Study 19601995 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (DRV/r)
Number of subjects: 0
Study 15733519 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 40
Study 15733519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12796602 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (C)
Number of subjects: 126
Study 12796602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate potassium and aztreonam (T/A)
Number of subjects: 126
Study 10596204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium priming (0.01 mg/kg)
Number of subjects: 45
Study 10596204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium priming (0.015 mg/kg)
Number of subjects: 45
Study 10596204 — intervention group
Group type: COMPARATOR
Intervention: Control (sodium chloride priming)
Number of subjects: 45
Study 8698586 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported morbidities and functional health status
Number of subjects: 100
Study 8698586 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and perceived health status, demographic characteristics, and diagnoses
Number of subjects: 100
Study 8698586 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional/perceived health status scales and disease classes
Number of subjects: 100
Study 1882007 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone, 15 mg per day
Number of subjects: 61
Study 1882007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 7050711 — intervention group
Group type: EXPERIMENTAL
Intervention: Zomepirac sodium
Number of subjects: 47
Study 7050711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31655801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stents
Number of subjects: 2201
Study 31655801 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 2201
Study 28981503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation of leaf of Juniperus excelsa extract plus cryotherapy
Number of subjects: 72
Study 28981503 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cryotherapy
Number of subjects: 72
Study 28981503 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation of leaf of Juniperus excelsa extract
Number of subjects: 72
Study 27017763 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (low-dose and addition of fentanyl): received intrathecally 0.5% hyperbaric bupivacaine (70% of group B) with fentanyl 20 mg and epidural catheter at T12‐L1.
Number of subjects: 60
Study 27017763 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (low-dose and epidural volume extension): received intrathecally 0.5% hyperbaric bupivacaine (70% of group B) and epidural catheter at L3‐4, with 10 ml saline injected 3 minutes after intrathecal injection.
Number of subjects: 60
Study 27017763 — intervention group
Group type: COMPARATOR
Intervention: Group B (conventional dose): received intrathecally 0.5% hyperbaric bupivacaine (10 mg; < 160 cm in height 11 mg; > 160 cm in height) and epidural catheter at T12‐L1.
Number of subjects: 60
Study 24463478 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil PCA
Number of subjects: 120
Study 24463478 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine bolus (0.5μg/kg) after delivery and sufentanil PCA
Number of subjects: 120
Study 24463478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine bolus (0.5μg/kg) after delivery and sufentanil with dexmedetomidine PCA (background infusion of 0.045μg/kg/h with a bolus of 0.07μg/kg)
Number of subjects: 120
Study 21870106 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (300 mg, t.i.d., p.o.)
Number of subjects: 0
Study 19608826 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alanyl-glutamine supplementation (0.5 g x kg(‐1) x d(‐1))
Number of subjects: 40
Study 19608826 — intervention group
Group type: COMPARATOR
Intervention: Control solution without alanyl-glutamine
Number of subjects: 40
Study 18215726 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/d for 6 weeks, then increased to 10 mg/d for 20 weeks)
Number of subjects: 28
Study 18215726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16383244 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy combined with choroid plexus cauterization (ETV-CPC); mean follow-up of 9.2 months.
Number of subjects: 550
Study 16383244 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic third ventriculostomy alone (ETV); mean follow-up of 19 months.
Number of subjects: 550
Study 16383244 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV-CPC in patients with myelomeningocele;
Number of subjects: 550
Study 16383244 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV-CPC in patients with nonpostinfectious hydrocephalus (NPIH);
Number of subjects: 550
Study 16383244 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV-CPC in patients with postinfectious hydrocephalus (PIH);
Number of subjects: 550
Study 16383244 — intervention group
Group type: COMPARATOR
Intervention: ETV and ETV-CPC for patients at least 1 year of age;
Number of subjects: 550
Study 16383244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical mortality rate;
Number of subjects: 550
Study 16383244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate;
Number of subjects: 550
Study 12401535 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate for 54 weeks
Number of subjects: 0
Study 12401535 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study 9803104 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound and plain film radiography evaluated by senior radiologists
Number of subjects: 95
Study 9803104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 95
Study 7647726 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex
Number of subjects: 27
Study 7647726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2694203 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 20
Study 2694203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 140698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 16
Study 140698 — intervention group
Group type: COMPARATOR
Intervention: Deptropine citrate
Number of subjects: 16
Study 140698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31790884 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 116
Study 31790884 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract rumination
Number of subjects: 116
Study 31790884 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete rumination
Number of subjects: 116
Study 30888593 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) with Modifast (800 kcal/day) during 2 weeks
Number of subjects: 62
Study 30888593 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acids (2 g/day) with a normal diet (2000 kcal/day) during 4 weeks
Number of subjects: 62
Study 27984004 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure strategy
Number of subjects: 505
Study 27984004 — intervention group
Group type: COMPARATOR
Intervention: Low positive end-expiratory pressure strategy
Number of subjects: 505
Study 26025322 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 1820
Study 23953895 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) - 4000 pulses at 0.25 mJ/mm² weekly for 4 weeks
Number of subjects: 70
Study 23953895 — intervention group
Group type: COMPARATOR
Intervention: Placebo - shockwave at 0 mJ/mm²
Number of subjects: 70
Study 21765233 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drain clamping for 2 hours without intraoperative bleeding control (Group A)
Number of subjects: 71
Study 21765233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative bleeding control without postoperative drain clamping (Group B)
Number of subjects: 71
Study 21765233 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 71
Study 19369294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg given twice on day 1 followed by 4 days of EE 20 microg
Number of subjects: 204
Study 19369294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg given twice on day 1 plus doxycycline 100 mg twice daily for 5 days
Number of subjects: 204
Study 19369294 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily for 5 days
Number of subjects: 204
Study 19369294 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily with EE 20 microg daily
Number of subjects: 204
Study 19369294 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 204
Study 17060732 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnification assessment with the Varioscope (7X magnification)
Number of subjects: 40
Study 17060732 — intervention group
Group type: COMPARATOR
Intervention: Control group using frozen section and permanent section analysis
Number of subjects: 40
Study 17060732 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnification assessment
Number of subjects: 40
Study 12548256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel gloves used 8 hours/day for 30 days
Number of subjects: 29